TSLA
Tesla
-- 379.280 NVDA
NVIDIA
-- 138.310 RGTI
Rigetti Computing
-- 20.0000 PLTR
Palantir
-- 75.190 AMD
Advanced Micro Devices
-- 120.630 
NEWS
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
IceCure Medical reported strong financial results for the first nine months of 2024, with 36% growth in ProSense® system and probe sales to $2.3M.
Gross profits increased 41%, with non-GAAP gross profits up 104%.
Gross margins improved to 43% from 37% year-over-year.
The FDA Advisory Panel voted favorably for ProSense®'s benefit-risk profile in early-stage low risk breast cancer, with a final FDA marketing authorization decision expected in Q1 2025.
The company maintained $10.7M in cash as of September 30, 2024, and raised $8.1M through share offerings. Research and development expenses decreased 15%, while sales and marketing expenses increased to support growth.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Samuel Lee : Bullish!!!